ISRCTN84226319已完成不适用
High-dose cytarabin versus low-dose cytarabin plus interferon-alpha-2a both followed by maintenance with interferon-alpha-2a in chronic myeloid leukemia
Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)0 个研究点目标入组 102 人开始时间: 2005年12月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 102
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Newly diagnosed patients with chronic myeloid leukemia (CML) in first chronic phase less than or equal to 6 months
- •2. Presence of Philadelphia chromosome or BCR/ABL rearrangement
- •3. Age 16 - 65 years inclusive
- •4. World Health Organisation (WHO) performance scale less than or equal to 2
排除标准
- •1. CML in blastic phase
- •2. CML in accelerated phase
- •3. Hepatic dysfunction (bilirubin greater than or equal to 2 x normal, and/or alanine aminotransferase [ALAT] greater than 4 x normal)
- •4. Renal dysfunction (creatinine greater 200 mumol/l or 23 mg/dl)
- •5. Patients with severe cardiac, pulmonary or neurologic disease
- •6. Pregnant or lactating females
- •7. Human immunodeficiency virus (HIV) infection
- •8. Other malignancies, except stage I cervix carcinoma and basocellular carcinoma
研究者
相似试验
已完成
不适用
High-dose cytarabin versus low-dose cytarabin plus interferon-alpha-2a both followed by maintenance with interferon-alpha-2a in chronic myeloid leukemia.NL-OMON27157Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl102
尚未招募
3 期
Comparison of a condensed schedule of high dose cytarabine consolidation to the conventional schedule of high dose cytarabine consolidation in the treatment of acute myeloid leukemiaCTRI/2020/05/025475Medical College Hospital Kolkata
招募中
不适用
Modified Low dose Cytarabine versus Hypomethylating agent in Elderly AML patients who are unfit for intensive chemotherapy: Randomized clinical studyDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0001891The Catholic University of Korea, Seoul St. Mary's Hospital50
已完成
2 期
A phase II trial of high dose cytarabine and fludarabine without anthracycline for patients with core binding factor acute myeloid leukaemia, measuring efficacy, safety and monitoring minimal residual diseaseCore binding factor acute myeloid leukaemiaCancer - Leukaemia - Acute leukaemiaACTRN12605000152628Australasian Leukaemia and Lymphoma Group53
已完成
4 期
Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AMLCore-Binding FactorAcute Myeloid LeukemiaNCT02926586Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine68